Department of Thoracic Surgery, Aichi Cancer Center Hospital, Nagoya, Japan.
J Thorac Oncol. 2010 Nov;5(11):1859-61. doi: 10.1097/JTO.0b013e3181f1c433.
Only the kinase domain of ERBB4 has been analyzed in East Asian populations, but a recent large-scale mutation analysis has indicated a higher incidence of mutations in the extracellular domain. Mutations in the extracellular and kinase domains of ERBB4 were examined by direct sequencing in 72 patients with primary lung cancer and 8 cell lines. In addition, ERBB4 expression was determined in 60 patients by quantitative real-time polymerase chain reaction. We investigated the relationship between ERBB4 expression and clinicopathologic characteristics including prognosis. One patient possessed Q793Q polymorphism in the kinase domain. However, we detected no mutations in extracellular or kinase domains of ERBB4. There was no significant difference in the clinicopathologic characteristics including prognosis of patients with high or low expression of ERBB4. The clinical significance of ERBB4 in lung cancers is negligible.
仅对东亚人群的 ERBB4 激酶结构域进行了分析，但最近的大规模突变分析表明，细胞外结构域的突变发生率更高。通过直接测序，在 72 例原发性肺癌患者和 8 个细胞系中检测 ERBB4 的细胞外和激酶结构域的突变。此外，通过实时定量聚合酶链反应在 60 例患者中确定 ERBB4 的表达。我们研究了 ERBB4 表达与包括预后在内的临床病理特征之间的关系。一名患者在激酶结构域中具有 Q793Q 多态性。然而，我们没有检测到 ERBB4 细胞外或激酶结构域的突变。ERBB4 高表达或低表达的患者的临床病理特征，包括预后，均无显著差异。ERBB4 在肺癌中的临床意义可以忽略不计。
